ANI Pharmaceuticals ANIP Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $92.15M+538% | $78.34M+523% | $40.57M+672% | -$10.21M-138% | -$21.05M-159% | ||
| $89.45M+17.8% | $91.42M+35.0% | $91.4M+51.5% | $84.52M+41.4% | $75.94M+27.0% | ||
| $39.25M+25.5% | $37.93M+29.3% | $35.22M+26.2% | $33.02M+27.7% | $31.28M+34.5% | ||
| $208.61M+158% | $185.23M+189% | $170.72M+83.8% | $139.14M+23.6% | $80.74M-30.3% | ||
| $17.44M+23.4% | $13.84M-14.8% | $14.99M-7.0% | $13.69M+5.0% | $14.13M+27.3% | ||
| -$25.8M+94.0% | -$34.32M+91.5% | -$43.6M+89.1% | -$435.96M-8,893% | -$433.5M-5,900% | ||
| $751K-53.8% | $1.16M-28.8% | $1.56M-3.8% | $1.63M0.0% | $1.63M0.0% | ||
| $21.96M+78.5% | $12.21M+11.4% | $11.92M+9.6% | $11.55M+6.4% | $12.3M+21.8% | ||
| $2.03M-99.3% | $0-100% | $297.09M+19,706% | $295.06M— | $293.78M— | ||
| —— | —— | —— | $279.38M— | $279.67M— | ||
| $161.38M+305% | $140.73M+285% | $117.63M+345% | -$22.28M-128% | -$78.76M-149% | ||
| $191.17M+187% | $171.39M+259% | $155.73M+103% | $125.44M+26.0% | $66.61M-36.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ANI Pharmaceuticals generate?
- ANI Pharmaceuticals (ANIP) generated $208.6M in operating cash flow over the trailing twelve months.
- What is ANI Pharmaceuticals's free cash flow?
- After $17.4M of capital expenditures, ANI Pharmaceuticals's free cash flow was $191.2M over the trailing twelve months, up 187.0% year over year.
- Where does ANI Pharmaceuticals's cash flow data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
